Evidence map›Paper›PMID 28098832›Full record

ReviewMolecules (Basel, Switzerland)2017

Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.

Patrizia Fasching, Martin Stradner, Winfried Graninger, Christian Dejaco, Johannes Fessler

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Drug design, development and therapy · 2025
    Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Patrizia FaschingDepartment of Rheumatology and Immunology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria. patriziafasching@gmx.at.
Martin StradnerDepartment of Rheumatology and Immunology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria. martin.stradner@medunigraz.at.
Winfried GraningerDepartment of Rheumatology and Immunology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria. winfried.graninger@medunigraz.at.
Christian DejacoDepartment of Rheumatology and Immunology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria. christian.dejaco@gmx.net.
Johannes FesslerDepartment of Rheumatology and Immunology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria. johannes_fessler@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A disruption of the crucial balance between regulatory T-cells (Tregs) and Th17-cells was recently implicated in various autoimmune disorders. Tregs are responsible for the maintenance of self-tolerance, thus inhibiting autoimmunity, whereas pro-inflammatory Th17-cells contribute to the induction and propagation of inflammation. Distortion of the Th17/Treg balance favoring the  pro-inflammatory Th17 side is hence suspected to contribute to exacerbation of autoimmune disorders. This review aims to summarize recent data and advances in targeted therapeutic modification of the Th17/Treg-balance, as well as information on the efficacy of candidate therapeutics with respect to the treatment of autoimmune diseases.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAutoimmune DiseasesForkhead Transcription FactorsGene Expression RegulationHumansImmunologic FactorsInflammationInterleukin-17Nuclear Receptor Subfamily 1, Group F, Member 3PiperidinesPyrimidinesPyrrolesSignal TransductionTh17 CellsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedForkhead Transcription FactorsFOXP3 protein, humanImmunologic FactorsInterleukin-17Nuclear Receptor Subfamily 1, Group F, Member 3PiperidinesPyrimidinesPyrrolesRORC protein, humansecukinumabsirukumabtofacitinibUstekinumabautoimmunityFoxp3regulatory T-cellsRORγtTh17-cells

Identifiers

PMID28098832
PMCPMC6155880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.